{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,27]],"date-time":"2026-09-27T14:45:44Z","timestamp":1790520344891,"version":"4.1.0"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"},{"start":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T00:00:00Z","timestamp":1612828800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc\/4.0"}],"funder":[{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"],"award-info":[{"award-number":["TAMOP-4.2.4.A\/2-11\/1-2012-0001"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100000780","name":"European Union","doi-asserted-by":"crossref","award":["GINOP-2.3.2-15-2016-00015"],"award-info":[{"award-number":["GINOP-2.3.2-15-2016-00015"]}],"id":[{"id":"10.13039\/501100000780","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/100004319","name":"Pfizer","doi-asserted-by":"publisher","award":["WI188341"],"award-info":[{"award-number":["WI188341"]}],"id":[{"id":"10.13039\/100004319","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Osteoporos Int"],"published-print":{"date-parts":[[2021,8]]},"DOI":"10.1007\/s00198-021-05871-0","type":"journal-article","created":{"date-parts":[[2021,2,9]],"date-time":"2021-02-09T23:46:57Z","timestamp":1612914417000},"page":"1621-1629","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":52,"title":["Effects of one-year tofacitinib therapy on bone metabolism in rheumatoid arthritis"],"prefix":"10.1007","volume":"32","author":[{"given":"A.","family":"Hamar","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7794-6844","authenticated-orcid":false,"given":"Z.","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Pusztai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Cz\u00f3kolyov\u00e1","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"E.","family":"V\u00e9gh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Z.","family":"Peth\u0151","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"N.","family":"Bodn\u00e1r","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Guly\u00e1s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c1.","family":"Horv\u00e1th","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"B.","family":"So\u00f3s","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"L.","family":"Bodoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"H. P.","family":"Bhattoa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Nagy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Tajti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Panyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"\u00c9.","family":"Szekanecz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Domj\u00e1n","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"K.","family":"Hodosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Sz\u00e1nt\u00f3","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Sz\u0171cs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Szamosi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,2,9]]},"reference":[{"key":"5871_CR1","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1136\/ard.57.6.325","volume":"57","author":"WF Lems","year":"1998","unstructured":"Lems WF, Dijkmans BA (1998) Should we look for osteoporosis in patients with rheumatoid arthritis? Ann Rheum Dis 57:325\u2013327","journal-title":"Ann Rheum Dis"},{"key":"5871_CR2","doi-asserted-by":"publisher","first-page":"313","DOI":"10.1016\/j.autrev.2017.01.014","volume":"16","author":"A Szentpetery","year":"2017","unstructured":"Szentpetery A, Horvath A, Gulyas K, Petho Z, Bhattoa HP, Szanto S, Szucs G, FitzGerald O, Schett G, Szekanecz Z (2017) Effects of targeted therapies on the bone in arthritides. Autoimmun Rev 16:313\u2013320","journal-title":"Autoimmun Rev"},{"key":"5871_CR3","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1007\/s11926-012-0253-7","volume":"14","author":"C Deal","year":"2012","unstructured":"Deal C (2012) Bone loss in rheumatoid arthritis: systemic, periarticular, and focal. Curr Rheumatol Rep 14:231\u2013237","journal-title":"Curr Rheumatol Rep"},{"key":"5871_CR4","doi-asserted-by":"publisher","first-page":"656","DOI":"10.1038\/nrrheum.2012.153","volume":"8","author":"G Schett","year":"2012","unstructured":"Schett G, Gravallese E (2012) Bone erosion in rheumatoid arthritis: mechanisms, diagnosis and treatment. Nat Rev Rheumatol 8:656\u2013664","journal-title":"Nat Rev Rheumatol"},{"key":"5871_CR5","doi-asserted-by":"publisher","first-page":"613720","DOI":"10.3389\/fmed.2020.613720","volume":"7","author":"D Rotta","year":"2020","unstructured":"Rotta D, Fassio A, Rossini M, Giollo A, Viapiana O, Orsolini G, Bertoldo E, Gatti D, Adami G (2020) Osteoporosis in inflammatory arthritides: new perspective on pathogenesis and treatment. Front Med 7:613720","journal-title":"Front Med"},{"key":"5871_CR6","doi-asserted-by":"publisher","first-page":"1725","DOI":"10.1080\/14656566.2020.1787381","volume":"21","author":"HG Raterman","year":"2020","unstructured":"Raterman HG, Bultink IE, Lems WF (2020) Osteoporosis in patients with rheumatoid arthritis: an update in epidemiology, pathogenesis, and fracture prevention. Expert Opin Pharmacother 21:1725\u20131737","journal-title":"Expert Opin Pharmacother"},{"key":"5871_CR7","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1038\/ncprheum0036","volume":"1","author":"G Schett","year":"2005","unstructured":"Schett G, Hayer S, Zwerina J, Redlich K, Smolen JS (2005) Mechanisms of disease: the link between RANKL and arthritic bone disease. Nat Clin Pract Rheumatol 1:47\u201354","journal-title":"Nat Clin Pract Rheumatol"},{"key":"5871_CR8","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1038\/nrrheum.2009.217","volume":"5","author":"H Takayanagi","year":"2009","unstructured":"Takayanagi H (2009) Osteoimmunology and the effects of the immune system on bone. Nat Rev Rheumatol 5:667\u2013676","journal-title":"Nat Rev Rheumatol"},{"key":"5871_CR9","doi-asserted-by":"crossref","unstructured":"Daoussis D, Andonopoulos AP, Liossis SN (2010) Wnt Pathway and IL-17: novel regulators of joint remodeling in rheumatic diseases. Looking beyond the RANK-RANKL-OPG axis. Semin Arthritis Rheum 39:369\u2013383","DOI":"10.1016\/j.semarthrit.2008.10.008"},{"key":"5871_CR10","doi-asserted-by":"publisher","first-page":"63","DOI":"10.1038\/nrrheum.2015.171","volume":"12","author":"IB McInnes","year":"2016","unstructured":"McInnes IB, Buckley CD, Isaacs JD (2016) Cytokines in rheumatoid arthritis - shaping the immunological landscape. Nat Rev Rheumatol 12:63\u201368","journal-title":"Nat Rev Rheumatol"},{"key":"5871_CR11","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1038\/nature01658","volume":"423","author":"WJ Boyle","year":"2003","unstructured":"Boyle WJ, Simonet WS, Lacey DL (2003) Osteoclast differentiation and activation. Nature 423:337\u2013342","journal-title":"Nature"},{"key":"5871_CR12","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1038\/nm1538","volume":"13","author":"D Diarra","year":"2007","unstructured":"Diarra D, Stolina M, Polzer K, Zwerina J, Ominsky MS, Dwyer D, Korb A, Smolen J, Hoffmann M, Scheinecker C, van der Heide D, Landewe R, Lacey D, Richards WG, Schett G (2007) Dickkopf-1 is a master regulator of joint remodeling. Nat Med 13:156\u2013163","journal-title":"Nat Med"},{"key":"5871_CR13","doi-asserted-by":"publisher","first-page":"473","DOI":"10.1038\/ncprheum0881","volume":"4","author":"G Schett","year":"2008","unstructured":"Schett G, Zwerina J, David JP (2008) The role of Wnt proteins in arthritis. Nat Clin Pract Rheumatol 4:473\u2013480","journal-title":"Nat Clin Pract Rheumatol"},{"key":"5871_CR14","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1016\/S0140-6736(94)91049-9","volume":"344","author":"AK Gough","year":"1994","unstructured":"Gough AK, Lilley J, Eyre S, Holder RL, Emery P (1994) Generalised bone loss in patients with early rheumatoid arthritis. Lancet 344:23\u201327","journal-title":"Lancet"},{"key":"5871_CR15","doi-asserted-by":"publisher","first-page":"535","DOI":"10.1136\/ard.48.7.535","volume":"48","author":"PN Sambrook","year":"1989","unstructured":"Sambrook PN, Cohen ML, Eisman JA, Pocock NA, Champion GD, Yeates MG (1989) Effects of low dose corticosteroids on bone mass in rheumatoid arthritis: a longitudinal study. Ann Rheum Dis 48:535\u2013538","journal-title":"Ann Rheum Dis"},{"key":"5871_CR16","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1007\/s10067-019-04771-3","volume":"39","author":"K Gulyas","year":"2020","unstructured":"Gulyas K, Horvath A, Vegh E et al (2020) Effects of 1-year anti-TNF-alpha therapies on bone mineral density and bone biomarkers in rheumatoid arthritis and ankylosing spondylitis. Clin Rheumatol 39:167\u2013175","journal-title":"Clin Rheumatol"},{"key":"5871_CR17","doi-asserted-by":"publisher","first-page":"420","DOI":"10.1196\/annals.1351.040","volume":"1069","author":"B Seriolo","year":"2006","unstructured":"Seriolo B, Paolino S, Sulli A, Ferretti V, Cutolo M (2006) Bone metabolism changes during anti-TNF-alpha therapy in patients with active rheumatoid arthritis. Ann N Y Acad Sci 1069:420\u2013427","journal-title":"Ann N Y Acad Sci"},{"key":"5871_CR18","doi-asserted-by":"crossref","unstructured":"Smolen JS, Landewe RBM, Bijlsma JWJ et al (2020) EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2019 update. Ann Rheum Dis 79:685\u2013699","DOI":"10.1136\/annrheumdis-2019-216655"},{"key":"5871_CR19","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.1136\/ard.2005.044198","volume":"65","author":"M Vis","year":"2006","unstructured":"Vis M, Havaardsholm EA, Haugeberg G, Uhlig T, Voskuyl AE, van de Stadt RJ, Dijkmans BA, Woolf AD, Kvien TK, Lems WF (2006) Evaluation of bone mineral density, bone metabolism, osteoprotegerin and receptor activator of the NFkappaB ligand serum levels during treatment with infliximab in patients with rheumatoid arthritis. Ann Rheum Dis 65:1495\u20131499","journal-title":"Ann Rheum Dis"},{"key":"5871_CR20","doi-asserted-by":"publisher","first-page":"353","DOI":"10.1136\/ard.2007.076604","volume":"67","author":"F Chopin","year":"2008","unstructured":"Chopin F, Garnero P, le Henanff A, Debiais F, Daragon A, Roux C, Sany J, Wendling D, Zarnitsky C, Ravaud P, Thomas T (2008) Long-term effects of infliximab on bone and cartilage turnover markers in patients with rheumatoid arthritis. Ann Rheum Dis 67:353\u2013357","journal-title":"Ann Rheum Dis"},{"key":"5871_CR21","first-page":"1753","volume":"34","author":"JH Woo","year":"2007","unstructured":"Woo JH, Lee HJ, Sung IH, Kim TH (2007) Changes of clinical response and bone biochemical markers in patients with ankylosing spondylitis taking etanercept. J Rheumatol 34:1753\u20131759","journal-title":"J Rheumatol"},{"issue":"Suppl 2","key":"5871_CR22","first-page":"ii67","volume":"63","author":"JJ O'Shea","year":"2004","unstructured":"O'Shea JJ (2004) Targeting the Jak\/STAT pathway for immunosuppression. Ann Rheum Dis 63(Suppl 2):ii67\u2013ii71","journal-title":"Ann Rheum Dis"},{"key":"5871_CR23","doi-asserted-by":"publisher","first-page":"21","DOI":"10.4049\/jimmunol.1401867","volume":"194","author":"AV Villarino","year":"2015","unstructured":"Villarino AV, Kanno Y, Ferdinand JR, O\u2019Shea JJ (2015) Mechanisms of Jak\/STAT signaling in immunity and disease. J Immunol 194:21\u201327","journal-title":"J Immunol"},{"key":"5871_CR24","doi-asserted-by":"publisher","first-page":"104609","DOI":"10.1016\/j.phrs.2019.104609","volume":"152","author":"R Roskoski Jr","year":"2020","unstructured":"Roskoski R Jr (2020) Properties of FDA-approved small molecule protein kinase inhibitors: A 2020 update. Pharmacol Res 152:104609","journal-title":"Pharmacol Res"},{"key":"5871_CR25","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1038\/nrrheum.2017.23","volume":"13","author":"KL Winthrop","year":"2017","unstructured":"Winthrop KL (2017) The emerging safety profile of JAK inhibitors in rheumatic disease. Nat Rev Rheumatol 13:234\u2013243","journal-title":"Nat Rev Rheumatol"},{"key":"5871_CR26","doi-asserted-by":"publisher","first-page":"559","DOI":"10.1002\/art.37816","volume":"65","author":"D van der Heijde","year":"2013","unstructured":"van der Heijde D, Tanaka Y, Fleischmann R, Keystone E, Kremer J, Zerbini C, Cardiel MH, Cohen S, Nash P, Song YW, Tegzov\u00e1 D, Wyman BT, Gruben D, Benda B, Wallenstein G, Krishnaswami S, Zwillich SH, Bradley JD, Connell CA, and the ORAL Scan Investigators (2013) Tofacitinib (CP-690,550) in patients with rheumatoid arthritis receiving methotrexate: twelve-month data from a twenty-four-month phase III randomized radiographic study. Arthritis Rheum 65:559\u2013570","journal-title":"Arthritis Rheum"},{"key":"5871_CR27","doi-asserted-by":"crossref","unstructured":"Labranche TP, Jesson MI, Radi ZA et al (2012) JAK inhibition with tofacitinib suppresses arthritic joint structural damage through decreased RANKL production. Arthritis Rheum 64:3531\u20133542","DOI":"10.1002\/art.34649"},{"key":"5871_CR28","doi-asserted-by":"publisher","first-page":"1024","DOI":"10.1136\/annrheumdis-2015-208267","volume":"75","author":"PG Conaghan","year":"2016","unstructured":"Conaghan PG, Ostergaard M, Bowes MA et al (2016) Comparing the effects of tofacitinib, methotrexate and the combination, on bone marrow oedema, synovitis and bone erosion in methotrexate-naive, early active rheumatoid arthritis: results of an exploratory randomised MRI study incorporating semiquantitative and quantitative techniques. Ann Rheum Dis 75:1024\u20131033","journal-title":"Ann Rheum Dis"},{"key":"5871_CR29","doi-asserted-by":"publisher","first-page":"727","DOI":"10.1007\/s10067-020-04930-x","volume":"39","author":"G Orsolini","year":"2020","unstructured":"Orsolini G, Bertoldi I, Rossini M (2020) Osteoimmunology in rheumatoid and psoriatic arthritis: potential effects of tofacitinib on bone involvement. Clin Rheumatol 39:727\u2013736","journal-title":"Clin Rheumatol"},{"key":"5871_CR30","doi-asserted-by":"publisher","first-page":"878","DOI":"10.1002\/art.40803","volume":"71","author":"D van der Heijde","year":"2019","unstructured":"van der Heijde D, Strand V, Tanaka Y et al (2019) Tofacitinib in combination with methotrexate in patients with rheumatoid arthritis: clinical efficacy, radiographic, and safety outcomes from a twenty-four-month, phase III study. Arthritis Rheum 71:878\u2013891","journal-title":"Arthritis Rheum"},{"key":"5871_CR31","doi-asserted-by":"publisher","DOI":"10.1371\/journal.pone.0181126","volume":"12","author":"K Murakami","year":"2017","unstructured":"Murakami K, Kobayashi Y, Uehara S, Suzuki T, Koide M, Yamashita T, Nakamura M, Takahashi N, Kato H, Udagawa N, Nakamura Y (2017) A Jak1\/2 inhibitor, baricitinib, inhibits osteoclastogenesis by suppressing RANKL expression in osteoblasts in vitro. PLoS One 12:e0181126","journal-title":"PLoS One"},{"key":"5871_CR32","doi-asserted-by":"publisher","first-page":"eaay4447","DOI":"10.1126\/scitranslmed.aay4447","volume":"12","author":"S Adam","year":"2020","unstructured":"Adam S, Simon N, Steffen U, Andes FT, Scholtysek C, M\u00fcller DIH, Weidner D, Andreev D, Kleyer A, Culemann S, Hahn M, Schett G, Kr\u00f6nke G, Frey S, Hueber AJ (2020) JAK inhibition increases bone mass in steady-state conditions and ameliorates pathological bone loss by stimulating osteoblast function. Sci Transl Med 12:eaay4447","journal-title":"Sci Transl Med"},{"key":"5871_CR33","doi-asserted-by":"publisher","first-page":"1461","DOI":"10.1093\/rheumatology\/kex258","volume":"57","author":"B Vidal","year":"2018","unstructured":"Vidal B, Cascao R, Finnila MAJ, Lopes IP, da Gloria VG, Saarakkala S, Zioupos P, Canhao H, Fonseca JE (2018) Effects of tofacitinib in early arthritis-induced bone loss in an adjuvant-induced arthritis rat model. Rheumatology (Oxford) 57:1461\u20131471","journal-title":"Rheumatology (Oxford)"},{"key":"5871_CR34","doi-asserted-by":"crossref","unstructured":"Gaber T, Brinkman ACK, Pienczikowski J, Diesing K, Damerau A, Pfeiffenberger M, Lang A, Ohrndorf S, Burmester GR, Buttgereit F, Hoff P (2020) Impact of Janus kinase inhibition with tofacitinib on fundamental processes of bone healing. Int J Mol Sci 21:865","DOI":"10.3390\/ijms21030865"},{"key":"5871_CR35","doi-asserted-by":"publisher","first-page":"557","DOI":"10.1016\/S0030-5898(20)30459-4","volume":"16","author":"HK Genant","year":"1985","unstructured":"Genant HK, Ettinger B, Cann CE, Reiser U, Gordan GS, Kolb FO (1985) Osteoporosis: assessment by quantitative computed tomography. Orthop Clin N Am 16:557\u2013568","journal-title":"Orthop Clin N Am"},{"key":"5871_CR36","doi-asserted-by":"publisher","first-page":"316","DOI":"10.1016\/S0001-2998(87)80024-7","volume":"17","author":"HK Genant","year":"1987","unstructured":"Genant HK, Block JE, Steiger P, Glueer CC, Smith R (1987) Quantitative computed tomography in assessment of osteoporosis. Semin Nucl Med 17:316\u2013333","journal-title":"Semin Nucl Med"},{"key":"5871_CR37","doi-asserted-by":"publisher","first-page":"123","DOI":"10.1016\/j.jocd.2007.12.010","volume":"11","author":"K Engelke","year":"2008","unstructured":"Engelke K, Adams JE, Armbrecht G, Augat P, Bogado CE, Bouxsein ML, Felsenberg D, Ito M, Prevrhal S, Hans DB, Lewiecki EM (2008) Clinical use of quantitative computed tomography and peripheral quantitative computed tomography in the management of osteoporosis in adults: the 2007 ISCD Official Positions. J Clin Densitom 11:123\u2013162","journal-title":"J Clin Densitom"},{"key":"5871_CR38","doi-asserted-by":"publisher","first-page":"1911","DOI":"10.3899\/jrheum.160645","volume":"43","author":"LS Tam","year":"2016","unstructured":"Tam LS (2016) The role of high-resolution peripheral quantitative computed tomography as a biomarker for joint damage in inflammatory arthritis. J Rheumatol 43:1911\u20131913","journal-title":"J Rheumatol"},{"key":"5871_CR39","doi-asserted-by":"publisher","first-page":"1271","DOI":"10.1007\/s00198-016-3850-x","volume":"28","author":"B Juhasz","year":"2017","unstructured":"Juhasz B, Gulyas K, Horvath A et al (2017) Comparison of peripheral quantitative computed tomography forearm bone density versus DXA in rheumatoid arthritis patients and controls. Osteoporos Int 28:1271\u20131277","journal-title":"Osteoporos Int"},{"key":"5871_CR40","doi-asserted-by":"publisher","first-page":"1580","DOI":"10.1136\/ard.2010.138461","volume":"69","author":"D Aletaha","year":"2010","unstructured":"Aletaha D, Neogi T, Silman AJ, Funovits J, Felson DT, Bingham CO, Birnbaum NS, Burmester GR, Bykerk VP, Cohen MD, Combe B, Costenbader KH, Dougados M, Emery P, Ferraccioli G, Hazes JM, Hobbs K, Huizinga TW, Kavanaugh A, Kay J, Kvien TK, Laing T, Mease P, Menard HA, Moreland LW, Naden RL, Pincus T, Smolen JS, Stanislawska-Biernat E, Symmons D, Tak PP, Upchurch KS, Vencovsky J, Wolfe F, Hawker G (2010) 2010 rheumatoid arthritis classification criteria: an American College of Rheumatology\/European League Against Rheumatism collaborative initiative. Ann Rheum Dis 69:1580\u20131588","journal-title":"Ann Rheum Dis"},{"key":"5871_CR41","doi-asserted-by":"publisher","first-page":"317","DOI":"10.1016\/j.ymeth.2005.11.010","volume":"38","author":"MF Elshal","year":"2006","unstructured":"Elshal MF, McCoy JP (2006) Multiplex bead array assays: performance evaluation and comparison of sensitivity to ELISA. Methods 38:317\u2013323","journal-title":"Methods"}],"container-title":["Osteoporosis International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s00198-021-05871-0\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s00198-021-05871-0.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2021,8,19]],"date-time":"2021-08-19T05:06:15Z","timestamp":1629349575000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s00198-021-05871-0"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,2,9]]},"references-count":41,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2021,8]]}},"alternative-id":["5871"],"URL":"https:\/\/doi.org\/10.1007\/s00198-021-05871-0","relation":{},"ISSN":["0937-941X","1433-2965"],"issn-type":[{"value":"0937-941X","type":"print"},{"value":"1433-2965","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,2,9]]},"assertion":[{"value":"27 November 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"1 February 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 February 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"None.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}